The discovery of two previously unreported mutations in the Dystrophin gene provides valuable insights into the diagnosis and management of Duchenne muscular dystrophy (DMD), according to a case study published recently in the Journal of Medical Case Reports.
This finding underscores the importance of genetic testing in cases where traditional diagnostic methods do not yield definitive results. By identifying these novel gene variants, researchers advanced the understanding of DMD and other dystrophinopathies, diseases caused by mutations in the DMD gene. This could lead to more effective treatments for patients affected by these muscle-wasting conditions.
In this case, a 12-year-old Syrian boy presented with a six-year history of increasing difficulty walking, recurrent falls and weakness in his lower limbs. Despite his symptoms, he maintained independent ambulation. A physical exam revealed a positive Gowers’ sign — an indication of muscle weakness — and calf enlargement, a common sign of DMD.
Laboratory tests showed highly elevated creatine kinase levels, suggesting muscle damage. A muscle biopsy confirmed dystrophic changes and partial dystrophin expression, supporting a diagnosis of a dystrophinopathy.
“The identification of novel variants in the DMD gene, alongside the absence of pathogenic mutations in other genes investigated by the neuromuscular panel, strongly suggests an X-linked dystrophinopathy diagnosis in our patient,” the authors of this study explained. They continued, “This case highlights the need for continued exploration of dystrophinopathies’ genetic variants.”
Read more about DMD testing and diagnosis
Initial genetic screening for large deletions or duplications in the Dystrophin gene was negative. However, further advanced genetic analysis uncovered two novel hemizygous variants: c.536A > T (p.Asp179Val) and c.680C > T (p.Ser227Phe). These missense mutations involve single amino acid changes rather than the more severe frameshift or nonsense mutations commonly associated with Duchenne muscular dystrophy.
Given the presence of Dystrophin in the biopsy, the findings aligned more closely with Becker muscular dystrophy than with DMD, a less severe form of the disease.
Dystrophin is crucial for maintaining muscle cell integrity: it links the inner structure of muscle cells to surrounding support structures. Mutations, also called “variants,” in the Dystrophin gene can lead to progressive muscle weakness, as seen in DMD and Becker muscular dystrophy. While frameshift mutations often result in the complete absence of the Dystrophin protein and more severe symptoms, missense mutations, like those identified in this patient, may allow for the production of a partially functional Dystrophin protein, leading to a milder disease course.
Identifying these novel mutations has significant implications for patient care. Early genetic diagnosis enables personalized disease management, including specialized physical therapy and potential future gene-based treatments. Understanding the specific genetic alterations also aids in risk assessment and family planning, offering valuable information for genetic counseling.
This case highlights the evolving landscape of muscular dystrophy research, demonstrating how advanced genetic analysis can provide critical answers for patients with unclear diagnoses. As research continues, these discoveries may contribute to improved therapeutic strategies, bringing hope for better disease management and potential targeted treatments in the future.
“Further studies are required to elucidate the functional impact of these novel variants and to improve our understanding of the genotypic and phenotypic variability observed in these disorders, which may lead to a revolution in treatment approaches and potentially offer curative options for patients,” concluded the authors.
Sign up here to get the latest news, perspectives, and information about DMD sent directly to your inbox. Registration is free and only takes a minute.
